Download PDF
Semin Liver Dis 2006; 26(4): 385-390
DOI: 10.1055/s-2006-951606
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Serum Markers of Hepatocellular Carcinoma

H.C. Spangenberg1 , R. Thimme1 , H.E. Blum1
  • 1Department of Medicine II, University Hospital, Freiburg, Germany
Further Information

Publication History

Publication Date:
18 October 2006 (online)

    Permissions and Reprints

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some areas of the world with increasing incidence worldwide. Most of patients with HCC are diagnosed at a late stage. Therefore, the prognosis of HCC patients is generally very poor with a 5-year survival rate of less than 5%. Screening strategies including α-fetoprotein (AFP) and ultrasound every 6 months in patients with liver cirrhosis, the major risk factor for HCC development, have been recommended to detect HCC at earlier stages amenable to effective treatment strategies. AFP, however, is a marker with poor sensitivity and specificity and the ultrasound is highly dependent on the operator's experience. Apart from AFP, lens culinaris agglutinin-reactive AFP and des-gamma carboxyprothrombin and several other biomarkers (e.g., glypican-3, human hepatocyte growth factor, and insulin-like growth factor) have been proposed as markers for HCC detection. In addition, with recently employed techniques, such as gene-expressing microarrays and proteomics, it is to be expected that new HCC-specific markers will become available in the near future. For all such proposed markers, however, the clinical usefulness has to be carefully evaluated and validated.

KEYWORDS

Tumor markers - α-fetoprotein - lens culinaris agglutinin-reactive AFP - des-gamma carboxyprothrombin

REFERENCES

  • 1 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
    CrossrefPubMedGoogle Scholar
  • 2 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.  J Hepatol. 2001;  35 421-430
    CrossrefPubMedGoogle Scholar
  • 3 Srinivas P R, Kramer B S, Srivastava S. Trends in biomarker research for cancer detection.  Lancet Oncol. 2001;  2 698-704
    CrossrefPubMedGoogle Scholar
  • 4 Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective.  J Nutr. 2002;  132 2471S-2475S
    PubMedGoogle Scholar
  • 5 Pepe M S, Etzioni R, Feng Z et al.. Phases of biomarker development for early detection of cancer.  J Natl Cancer Inst. 2001;  93 1054-1061
    CrossrefPubMedGoogle Scholar
  • 6 Collier J, Sherman M. Screening for hepatocellular carcinoma.  Hepatology. 1998;  27 273-278
    CrossrefPubMedGoogle Scholar
  • 7 Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.  Hepatology. 1995;  22 432-438
    CrossrefPubMedGoogle Scholar
  • 8 Trevisani F, D'Intino P E, Morselli-Labate A M et al.. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.  J Hepatol. 2001;  34 570-575
    CrossrefPubMedGoogle Scholar
  • 9 Peng Y C, Chan C S, Chen G H. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma.  Hepatogastroenterology. 1999;  46 3208-3211
    PubMedGoogle Scholar
  • 10 Cedrone A, Covino M, Caturelli E et al.. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.  Hepatogastroenterology. 2000;  47 1654-1658
    PubMedGoogle Scholar
  • 11 Gambarin-Gelwan M, Wolf D C, Shapiro R et al.. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation.  Am J Gastroenterol. 2000;  95 1535-1538
    CrossrefPubMedGoogle Scholar
  • 12 Nguyen M H, Garcia R T, Simpson P W et al.. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.  Hepatology. 2002;  36 410-417
    CrossrefPubMedGoogle Scholar
  • 13 Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: a systematic review and critical analysis.  Ann Intern Med. 2003;  139 46-50
    PubMedGoogle Scholar
  • 14 Taketa K, Sekiya C, Namiki M et al.. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions.  Gastroenterology. 1990;  99 508-518
    PubMedGoogle Scholar
  • 15 Johnson P J, Poon T C, Hjelm N M et al.. Structures of disease-specific serum alpha-fetoprotein isoforms.  Br J Cancer. 2000;  83 1330-1337
    CrossrefPubMedGoogle Scholar
  • 16 Taketa K, Okada S, Win N et al.. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar.  Acta Med Okayama. 2002;  56 317-320
    PubMedGoogle Scholar
  • 17 Khien V V, Mao H V, Chinh T T et al.. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma.  Int J Biol Markers. 2001;  16 105-111
    PubMedGoogle Scholar
  • 18 Yoshida S, Kurokohchi K, Arima K et al.. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma.  Int J Oncol. 2002;  20 305-309
    PubMedGoogle Scholar
  • 19 Wang S S, Lu R H, Lee F Y et al.. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.  J Hepatol. 1996;  25 166-171
    CrossrefPubMedGoogle Scholar
  • 20 Taketa K, Endo Y, Sekiya C et al.. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma.  Cancer Res. 1993;  53 5419-5423
    PubMedGoogle Scholar
  • 21 Oka H, Saito A, Ito K et al.. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein.  J Gastroenterol Hepatol. 2001;  16 1378-1383
    CrossrefPubMedGoogle Scholar
  • 22 Shiraki K, Takase K, Tameda Y et al.. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients.  Hepatology. 1995;  22 802-807
    CrossrefPubMedGoogle Scholar
  • 23 Sato Y, Nakata K, Kato Y et al.. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein.  N Engl J Med. 1993;  328 1802-1806
    CrossrefPubMedGoogle Scholar
  • 24 Liebman H A, Furie B C, Tong M J et al.. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.  N Engl J Med. 1984;  310 1427-1431
    CrossrefPubMedGoogle Scholar
  • 25 Liebman H A. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin.  Cancer Res. 1989;  49 6493-6497
    PubMedGoogle Scholar
  • 26 Ono M, Ohta H, Ohhira M et al.. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis.  Tumour Biol. 1990;  11 319-326
    PubMedGoogle Scholar
  • 27 Aoyagi Y, Oguro M, Yanagi M et al.. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.  Cancer. 1996;  77 1781-1786
    CrossrefPubMedGoogle Scholar
  • 28 Mita Y, Aoyagi Y, Yanagi M et al.. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.  Cancer. 1998;  82 1643-1648
    CrossrefPubMedGoogle Scholar
  • 29 Nomura F, Ishijima M, Kuwa K et al.. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.  Am J Gastroenterol. 1999;  94 650-654
    CrossrefPubMedGoogle Scholar
  • 30 Lamerz R, Runge M, Stieber P et al.. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.  Anticancer Res. 1999;  19 2489-2493
    PubMedGoogle Scholar
  • 31 Grazi G L, Mazziotti A, Legnani C et al.. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.  Liver Transpl Surg. 1995;  1 249-255
    CrossrefPubMedGoogle Scholar
  • 32 Marrero J A, Su G L, Wei W et al.. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients.  Hepatology. 2003;  37 1114-1121
    CrossrefPubMedGoogle Scholar
  • 33 Izuno K, Fujiyama S, Yamasaki K et al.. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.  Hepatogastroenterology. 1995;  42 387-393
    PubMedGoogle Scholar
  • 34 Ikoma J, Kaito M, Ishihara T et al.. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.  Hepatogastroenterology. 2002;  49 235-238
    PubMedGoogle Scholar
  • 35 Ishii M, Gama H, Chida N et al.. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.  Am J Gastroenterol. 2000;  95 1036-1040
    PubMedGoogle Scholar
  • 36 Shimauchi Y, Tanaka M, Kuromatsu R et al.. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.  Oncol Rep. 2000;  7 249-256
    PubMedGoogle Scholar
  • 37 Okuda H, Nakanishi T, Takatsu K et al.. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.  J Gastroenterol Hepatol. 2001;  16 1290-1296
    CrossrefPubMedGoogle Scholar
  • 38 Hamamura K, Shiratori Y, Shiina S et al.. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.  Cancer. 2000;  88 1557-1564
    CrossrefPubMedGoogle Scholar
  • 39 Weitz I C, Liebman H A. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review.  Hepatology. 1993;  18 990-997
    PubMedGoogle Scholar
  • 40 Fujiyama S, Tanaka M, Maeda S et al.. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma.  Oncology. 2002;  62(suppl 1) 57-63
    CrossrefPubMedGoogle Scholar
  • 41 Filmus J, Church J G, Buick R N. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine.  Mol Cell Biol. 1988;  8 4243-4249
    PubMedGoogle Scholar
  • 42 Bernfield M, Gotte M, Park P W et al.. Functions of cell surface heparan sulfate proteoglycans.  Annu Rev Biochem. 1999;  68 729-777
    CrossrefPubMedGoogle Scholar
  • 43 Zhu Z W, Friess H, Wang L et al.. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.  Gut. 2001;  48 558-564
    CrossrefPubMedGoogle Scholar
  • 44 Hsu H C, Cheng W, Lai P L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.  Cancer Res. 1997;  57 5179-5184
    PubMedGoogle Scholar
  • 45 Nakatsura T, Yoshitake Y, Senju S et al.. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.  Biochem Biophys Res Commun. 2003;  306 16-25
    CrossrefPubMedGoogle Scholar
  • 46 Capurro M, Wanless I R, Sherman M et al.. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.  Gastroenterology. 2003;  125 89-97
    CrossrefPubMedGoogle Scholar
  • 47 Hippo Y, Watanabe K, Watanabe A et al.. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.  Cancer Res. 2004;  64 2418-2423
    CrossrefPubMedGoogle Scholar
  • 48 Kladney R D, Bulla G A, Guo L et al.. GP73, a novel Golgi-localized protein upregulated by viral infection.  Gene. 2000;  249 53-65
    CrossrefPubMedGoogle Scholar
  • 49 Marrero J A, Romano P R, Nikolaeva O et al.. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.  J Hepatol. 2005;  43 1007-1012
    CrossrefPubMedGoogle Scholar
  • 50 Nakamura T. Structure and function of hepatocyte growth factor.  Prog Growth Factor Res. 1991;  3 67-85
    CrossrefPubMedGoogle Scholar
  • 51 Tomiya T, Tani M, Yamada S et al.. Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients.  Gastroenterology. 1992;  103 1621-1624
    PubMedGoogle Scholar
  • 52 Tomiya T, Nagoshi S, Fujiwara K. Significance of serum human hepatocyte growth factor levels in patients with hepatic failure.  Hepatology. 1992;  15 1-4
    PubMedGoogle Scholar
  • 53 Shiota G, Okano J, Kawasaki H et al.. Serum hepatocyte growth factor levels in liver diseases: clinical implications.  Hepatology. 1995;  21 106-112
    CrossrefPubMedGoogle Scholar
  • 54 Yanagawa K, Yamashita T, Yada K et al.. The antiproliferative effect of HGF on hepatoma cells involves induction of apoptosis with increase in intracellular polyamine concentration levels.  Oncol Rep. 1998;  5 185-190
    PubMedGoogle Scholar
  • 55 Yamagamim H, Moriyama M, Matsumura H et al.. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases.  Cancer. 2002;  95 824-834
    CrossrefPubMedGoogle Scholar
  • 56 Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?.  Cancer Res. 1995;  55 249-252
    PubMedGoogle Scholar
  • 57 Baserga R, Hongo A, Rubini M et al.. The IGF-I receptor in cell growth, transformation and apoptosis.  Biochim Biophys Acta. 1997;  1332 F105-F126
    PubMedGoogle Scholar
  • 58 Resnicoff M, Abraham D, Yutanawiboonchai W et al.. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo.  Cancer Res. 1995;  55 2463-2469
    PubMedGoogle Scholar
  • 59 Mazziotti G, Sorvillo F, Morisco F et al.. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.  Cancer. 2002;  95 2539-2545
    CrossrefPubMedGoogle Scholar
  • 60 Moon W S, Rhyu K H, Kang M J et al.. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?.  Mod Pathol. 2003;  16 552-557
    CrossrefPubMedGoogle Scholar
  • 61 Poon R T, Ho J W, Tong C S et al.. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.  Br J Surg. 2004;  91 1354-1360
    CrossrefPubMedGoogle Scholar
  • 62 Sacco R, Leuci D, Tortorella C et al.. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.  Cytokine. 2000;  12 811-814
    CrossrefPubMedGoogle Scholar
  • 63 Song B C, Chung Y H, Kim J A et al.. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma.  Cancer. 2002;  94 175-180
    CrossrefPubMedGoogle Scholar
  • 64 Tangkijvanich P, Tosukhowong P, Bunyongyod P et al.. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.  Southeast Asian J Trop Med Public Health. 1999;  30 110-114
    PubMedGoogle Scholar
  • 65 Ishizuka H, Nakayama T, Matsuoka S et al.. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity.  Intern Med. 1999;  38 927-931
    PubMedGoogle Scholar

P.D. Dr. H.C. Spangenberg

Department of Medicine II, University Hospital

Hugstetter Strasse 55, D-79106 Freiburg, Germany

      >